Cardiorenal syndrome (CRS) is a group of disorders in which heart or kidney dysfunction worsens each other. This study aimed to explore the improvement effect of nicorandil on cardiorenal injury in patients with type I CRS. Patients with coronary heart disease complicated with type I CRS were enrolled. Based on the conventional treatment, the patients were prospectively randomized into a conventional treatment group and a nicorandil group, which was treated with 24 mg/d nicorandil intravenously for 1 week. Fasting peripheral venous blood serum and urine were collected before and at the end of treatment. An automatic biochemical analyzer and enzyme linked immunosorbent assay were used to detect B-type brain natriuretic peptide (BNP), serum creatinine (Scr) and cystatin C (Cys-C), renal injury index-kidney injury molecule-1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL), and interleukin-18 (IL-18) levels. The left ventricular ejection fraction was measured by echocardiography. All measurements were not significantly different between the nicorandil and conventional treatment groups before treatment (all P > 0.05), and BNP, Scr, Cys-C, NGAL, KIM-1, and IL-18 were decreased in the 2 groups at the end of treatment (all P < 0.05). Compared with the conventional treatment group, BNP, Scr, Cys-C, NGAL, KIM-1, and IL-18 were more significantly decreased in the nicorandil group (all P < 0.05) and left ventricular ejection fraction was more significantly increased (P < 0.05). Therefore, nicorandil could significantly improve the cardiac and renal function of patients with type I CRS. This may prove to be a new therapeutic tool for improving the prognosis and rehabilitation of type I CRS.

中文翻译：

---

尼可地尔可减少患有 I 型心肾综合征的冠心病患者的肾损伤。

心肾综合征（CRS）是一组心脏或肾脏功能障碍相互恶化的疾病。本研究旨在探讨尼可地尔对I型CRS患者心肾损伤的改善作用。纳入患有冠心病并发I型CRS的患者。在常规治疗的基础上，前瞻性随机分为常规治疗组和尼可地尔组，给予尼可地尔24 mg/d静脉注射，疗程1周。治疗前和治疗结束时采集空腹外周静脉血、血清和尿液。采用全自动生化分析仪和酶联免疫吸附法检测B型脑钠肽（BNP）、血清肌酐（Scr）、胱抑素C（Cys-C）、肾损伤指数-肾损伤分子-1（KIM-1）。 )、中性粒细胞明胶酶相关脂质运载蛋白 (NGAL) 和白细胞介素 18 (IL-18) 水平。通过超声心动图测量左心室射血分数。尼可地尔治疗组与常规治疗组治疗前各项指标均无显着性差异（均P>0.05），且治疗结束时两组BNP、Scr、Cys-C、NGAL、KIM-1、IL-18均下降治疗（所有 P < 0.05）。与常规治疗组比较，尼可地尔组 BNP、Scr、Cys-C、NGAL、KIM-1、IL-18 降低更显着​​（均 P < 0.05），左室射血分数升高更显着（P < 0.05）。因此，尼可地尔可以显着改善I型CRS患者的心肾功能。这可能被证明是改善 I 型 CRS 预后和康复的新治疗工具。